INTEST CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INTEST CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $19.38M | Mar 28, 2018 |
| FY2017 | Sep 30, 2017 | $17.35M | Mar 28, 2018 |
| FY2017 | Jun 30, 2017 | $15.89M | Mar 28, 2018 |
| FY2017 | Mar 31, 2017 | $14.18M | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | $10.27M | Mar 28, 2018 |
| FY2017 | Sep 30, 2016 | $10.82M | Mar 28, 2018 |
| FY2017 | Jun 30, 2016 | $10.49M | Mar 28, 2018 |
| FY2017 | Mar 31, 2016 | $8.65M | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $7.94M | Mar 27, 2017 |
| FY2016 | Sep 30, 2015 | $9.20M | Mar 27, 2017 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $47.27M | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $46.20M | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.92M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $14.54M | Mar 13, 2025 |
| FY2024 | Sep 30, 2024 | $14.01M | Mar 13, 2025 |
| FY2024 | Jun 30, 2024 | $13.80M | Mar 13, 2025 |
| FY2024 | Mar 31, 2024 | $13.08M | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $12.45M | Mar 13, 2025 |
| FY2024 | Sep 30, 2023 | $14.45M | Mar 13, 2025 |
| FY2024 | Jun 30, 2023 | $15.03M | Mar 13, 2025 |
| FY2024 | Mar 31, 2023 | $15.05M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $14.98M | Mar 27, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.53M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $1.50M | Mar 13, 2025 |
| FY2024 | Sep 30, 2024 | $495.0K | Mar 13, 2025 |
| FY2024 | Jun 30, 2024 | $230.0K | Mar 13, 2025 |
| FY2024 | Mar 31, 2024 | $662.0K | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $1.46M | Mar 13, 2025 |
| FY2024 | Sep 30, 2023 | $2.28M | Mar 13, 2025 |
| FY2024 | Jun 30, 2023 | $2.79M | Mar 13, 2025 |
| FY2024 | Mar 31, 2023 | $2.82M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.24M | Mar 27, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.73M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.39M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $10.44M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $10.72M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $8.46M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($1.22M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.55M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $5.18M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $3.61M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $4.15M | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.44M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $8.55M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $7.62M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $7.53M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.53M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $5.07M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $4.96M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $4.91M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $4.30M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $3.66M | Mar 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.32M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.82M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $16.20M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($1.39M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $10.84M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.25M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($8.41M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $10.96M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $7.24M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $4.29M | Mar 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.32M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.29M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.37M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $994.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $658.0K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $620.0K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.21M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $745.0K | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $339.0K | Mar 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.31M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $152.29M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $134.83M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $110.07M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $103.91M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $62.03M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $59.72M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $67.19M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $62.49M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $42.84M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $52.50M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $38.55M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $45.11M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $49.08M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $17.28M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $14.88M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $24.31M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $23.21M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $5.06M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.62M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $99.79M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $96.28M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $64.96M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $54.82M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $44.75M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $44.83M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $42.88M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $39.29M | Mar 23, 2020 |
| FY2018 | Dec 31, 2016 | $37.79M | Mar 26, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.36M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $30.74M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $21.73M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $21.61M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $21.45M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $13.74M | Mar 22, 2023 |
| FY2020 | Dec 31, 2019 | $13.74M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $13.74M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $13.74M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.71M | Mar 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.56M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $45.09M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $42.20M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $32.85M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $24.39M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $17.11M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $18.01M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $15.68M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $12.65M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | $11.67M | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.22M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $19.83M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $45.26M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $13.43M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $21.20M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $10.28M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $7.61M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $17.86M | Mar 23, 2020 |
| FY2019 | Dec 31, 2017 | $13.29M | Mar 23, 2020 |
| FY2018 | Dec 31, 2016 | $28.61M | Mar 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.94M | Mar 13, 2025 |
| FY2023 | Dec 31, 2023 | $12.04M | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $16.14M | Mar 22, 2023 |
| FY2021 | Dec 31, 2021 | $20.10M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 13, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 13, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 13, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 13, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.49M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 12.38M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 12.17M | Mar 13, 2025 |